International experts discuss the clinical applications of the magnetoencephalography (MEG).

– the meeting held last Friday, June 15, was held within the framework of the project NEUROTEC, dedicated to the research of new technologies for the knowledge of Alzheimer’s

– reviewed new potential applications, such as: MEG as a biomarker of HIV-associated neurocognitive disorder; magnetoencelalografia in patients with autism, or the measurement of functional neurotransmission in the investigation of the Alzheimer’s disease

Madrid, June 2012.- international experts will analyze clinical application of magnetoencephalography (MEG), in the center of Biomedida technology of Madrid (CTB) day Magnetoencephalography: from research to clinical applications, sponsored by Elekta. The meeting brought together experts in clinical and research in the fields of epilepsy, Alzheimer’s disease, autism or severe neurological injuries, to analyze the latest technological advances in the prevention, knowledge and treatment of neurological diseases.

The Symposium, sponsored by Elekta, within the framework of their agreement of cooperation and support with the CBT research took place on Friday, June 15. The day was held in the framework of the activities included in the draft of the autonomous community of Madrid NEUROTEC, dedicated to the research of new technologies that help to improve the knowledge of Alzheimer’s disease.

The CTB is a leading center in the Alzheimer’s disease research and clinical research of Elekta Neuromag with magnetoencephalography. At the international level, the group responsible for the MEG is one of the pioneers and greater number of publications in MEG-Alzheimer. Elekta is a company specialized in the health care, pioneer in innovative clinical solutions for treating cancer and brain disorders.

Topics addressed by the international experts during the meeting include potential new applications of MEG as a biomarker of; HIV-associated neurocognitive disorder The magnetoencelalografia in patients with autism or the measurement of functional neurotransmission in Alzheimer’s research.

During the day at the headquarters of the CTB, at the Universidad Politécnica de Madrid (Montegancedo Campus) were also analysed aspects as the reorganization of the neurological networks after severe neurological trauma; By MEG or clinical MEG Presurgical planning: health insurance coverage and reimbursement.

For Fernando Maestu, director of the laboratory of cognitive neuroscience of the CTB, this session ofreceuna new vision of the magnetoencephalography, a technique essentially devoted to research a technique with great potential for clinical application ”.

For its part, Eduardo Rodríguez Urcelay, director of Elekta Iberia, it has highlighted the great medical and scientific interest of the day for the future of the prevention and treatment of neurological diseases. The aim of this Conference is to contribute to the clinical application of advances in the Neurosciences research through the exchange of experiences in different fields, where Spain and CTB are world leader, as it is the case of Alzheimer’s, and broaden the spectrum to other pathologiescontributing to the improvement of the treatments and the quality of life of the patient. From Elekta provide our technological ability and know-how through our system of magnetoencephalography Neuromag. ”

Elekta Neuromag is an advanced system of magnetoencephalography that allows real-time mapping of brain functional activity through non-invasive techniques, through the acquisition of magnetic fieldsallowing to investigate the relationship between brain structures and their functions.

About Elekta

Elekta is a company specialized in the health care pioneer in innovative clinical solutions for treating cancer and brain disorders. The company develops tools of high technology and sophisticated systems of planning for radiotherapy and radiosurgery, brachytherapy, and software for the optimization of the flow of work across the spectrum of cancer treatment. Expanding the bounds of science and technology, offering smart and efficient solutions that provide security professionals of health and patients, Elekta aims improve, prolong and save the lives of patients.

Today, Elekta solutions for Oncology and Neurosurgery are used in more than 6,000 hospitals throughout the world. Elekta has nearly 3,300 employees in total. With headquarters in Stockholm, Sweden, it is listed on the Nordic Exchange under the ticker EKTAb.